industry feedback, page-7

Prima has a good product with good potential but does not have the size, influence or capability to take it to market

That's a very good summary where Prima stands atm and why the sp hovers around the current levels.

I was puzzled for some time why would a small bio company set the PIII trial on such a big (~expensive) number of patients (~800), ~100 (150) centers, 3 manufacturing facilities? Normal PIII trials involve only ~300-400 patients.

I guess this may be a long shot investment plan into marketing and manufacturing prototype.
If you think about how many hospitals, clinics, doctors, medics, various medical services are involved across 3 vast geographical areas and no doubt they will follow the results..this should pay it off.

Well, back to our daily obstacles and routine :), the Prima web site was updated last night with new calendar events and new "old" presentation. Nothing new, just a bit of info to past another day :)